Marisa Wexler MS,  —

Variations in the LTA gene can alter a person’s risk of developing ankylosing spondylitis (AS), a new study suggests. The study, “Associations of lymphotoxin-a (LTA) rs909253 A/G gene polymorphism, plasma level and risk of ankylosing spondylitis in a Chinese Han population,” was published in the journal…

Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA). The medication is used to treat nr-axSpA patients with evidence of active inflammation, as indicated by magnetic resonance imaging and/or levels of the blood marker C-reactive…

Mabpharm has filed an application with China’s National Medical Products Administration (NMPA) seeking approval of a biobetter of infliximab, a biological treatment for people with ankylosing spondylitis and other inflammatory disorders. Sorrento Therapeutics, the company owning global rights to the biobetter antibody outside of China,…

The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated due to inflammation when treatment is started, new research suggests. The findings were presented in a session, titled “Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients…

Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were discussed at the 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in a presentation, titled…

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat people with seven inflammatory diseases, including adults with ankylosing spondylitis. Pfizer, the company that developed Abrilada, expects the therapy to be available in the U.S. starting in 2023.

Treatment with the experimental therapy bimekizumab is safe and shows sustained efficacy over 48 weeks in people with ankylosing spondylitis (AS), data from a Phase 2b trial show. In addition, the use of biologic therapies for AS is associated with more comorbidities and higher use of other treatments…

The European Commission has approved a label update for Cosentyx (secukinumab) that will allow healthcare providers to prescribe doses of up to 300 mg — twice what was previously approved — for people with active ankylosing spondylitis (AS). Cosentyx, developed and marketed by Novartis, is a…

Depression is more common among people with ankylosing spondylitis (AS) than in the general population, with about a third of patients experiencing depressive symptoms, a meta-analysis reveals. The study, “Prevalence of Depression in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis,” was published in the…

People who are diagnosed with ankylosing spondylitis (AS) are more likely to have had tonsillitis than those without this disease, a study found, suggesting that tonsillitis might predispose a person for AS. “Association between tonsillitis and newly diagnosed ankylosing spondylitis: A nationwide, population-based, case-control study” was published…